Clinical Trials
7
Active:0
Completed:6
Trial Phases
2 Phases
Phase 1:2
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Phase 1
2 (40.0%)Replicor Compassionate Access Program
- Conditions
- Viral Hepatitis BViral Hepatitis DCirrhosis, LiverDecompensated CirrhosisAscites HepaticVarices, EsophagealHepatocellular Carcinoma
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Replicor Inc.
- Registration Number
- NCT05683548
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
🇫🇷AP-HP Hôpital Beaujon, Clichy, France
🇫🇷CHU Lille, Lille, France
A Long Term Follow-up Study of Patients From the REP 301 Protocol
Completed
- Conditions
- Hepatitis D, ChronicHepatitis B, Chronic
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02876419
- Locations
- 🇲🇩
Infectious Clinical Hospital (n.a. Toma Ciorba), Chisinau, Moldova, Republic of
Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
Phase 2
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02726789
Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02646163
- Locations
- 🇧🇩
Farabi General Hospital, Dhaka, Bangladesh
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Phase 1
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02646189
- Locations
- 🇧🇩
Farabi General Hospital, Dhaka, Bangladesh
- Prev
- 1
- 2
- Next
News
No news found